Effect of Celecoxib in the prevention of pancreatitis after Endoscopic retrograde cholangiopancreatography (ERCP)
Not Applicable
- Conditions
- Acute Pancreatitis.Other acute pancreatitis
- Registration Number
- IRCT201207252417N8
- Lead Sponsor
- Vice Chancellor for Research, Isfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 76
Inclusion Criteria
1- no advanced systemic disease
2- no addiction
3- no continouse drug use
4- mild hepatobilliary disease with liver enzyme elevation to 4 times of normal upper limit.
5- without fibrosis, cirrhosis or infectious hepatitis
exclusion criteria:
1- other side effects except pancreatitis after ERCP
2- Lack of consent to cooperate in trial.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pancreatitis. Timepoint: Befor and 2 hours after Endoscopic retrograde cholangiopancreatography. Method of measurement: Pain and clinical signs.;Serum amylase level. Timepoint: Befor and 2 hours after Endoscopic retrograde cholangiopancreatography. Method of measurement: ELISA kits: International Unit per Littre.
- Secondary Outcome Measures
Name Time Method